诺和诺德(NVO.US)盘中一度涨近5%，报51.08美元。消息面上，诺和诺德主要竞争对手礼来的减肥药显示出的效果不及其畅销药Wegovy。 礼来在周四的声明中表示，一项后期研究发现，其实验性GLP-1药片使患者在72周后平均减轻了12.4%的体重。在参与研究的3000多人中，那些接受安慰剂的人减轻了0.9%的体重。 礼来高管一直将这种名为orforglipron的每日一次口服药片宣传为最近流行的肥胖注射剂的更便宜替代品，如其Zepbound产品或诺和诺德的Wegovy。这两种药物目前是肥胖药物市场的主要支柱，预计该市场在下一个十年初期将增长至1500亿美元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.